Potential of epigenetic therapies in the management of solid tumors

Cancer Management and Research

Volumn 7, Issue , 2015, Pages 241-251

  Valdespino, Victor ^a   Valdespino, Patricia M ^b  

^a UNIVERSIDAD AUTÓNOMA METROPOLITANA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Epigenetic therapy; Solid tumor; Targeted therapy; Treatment

Indexed keywords

AZACITIDINE; BELINOSTAT; DECITABINE; ROMIDEPSIN; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER EPIDEMIOLOGY; CANCER THERAPY; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DRUG APPROVAL; EPIGENETIC CANCER THERAPY; EPIGENETICS; GENOTYPE; HEMATOPOIETIC SYSTEM TUMOR; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; LEUKEMIA; MOLECULAR PATHOLOGICAL EPIDEMIOLOGY; MOLECULAR PATHOLOGY; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; OVARY CARCINOMA; PLEURA TUMOR; SOLID TUMOR; UTERINE CERVIX CARCINOMA;

EID: 84940031174     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S70358     Document Type: Article

References (53)

1. Kanwal R, Gupta K, Gupta S. Cancer epigenetics: an introduction. Methods Mol Biol. 2015;1238:3–25.
2. Hanahan D, Weinberg R. The hallmarks of cancer. Cell. 2000;100: 57–70.
3. Valdespino VM, Valdespino VE. Alteraciones celulares y moleculares no clasicas en el desarrollo del cáncer [Non classical cellular and molecular deficits in cancer development]. Gac Med Mex. 2010;146:185–198. Spanish.
4. Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
5. Sieggens L, Ekwall K. Epigenetics, chromatin and genome organization: recent advances from the ENCODE project. J Intern Med. 2014;276: 201–214.
6. Valdespino V, Valdespino PM, Valdespino V Jr. Main phenotype subphases in reprogramming somatic cells as a model of cellular differentiation process. Am J Biomed Res. 2013;1:48–56.
7. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblast by defined factors. Cell. 2007;131: 861–872.
8. Campos-Sanchez E, Cobaleda C. Tumoral reprogramming: plasticity takes a walk on the wild side. Biochim Biophys Acta. 2015;1849: 436–447.
9. Burgio E, Migliore L. Towards a systemic paradigm in carcinogenesis: linking epigenetics and genetics. Mol Biol Rep. 2015;42:777–790.
10. Goding CR, Pei D, Lu X. Cancer: pathological nuclear reprogramming? Nat Rev Cancer. 2014;14:568–573.
11. Kanherkar RR, Bhatia-Dey N, Makarev E, Csoka AB. Cellular reprogramming for understanding and treating human disease. Front Cell Dev Biol. 2014;2:67.
12. Shukla S, Meeran SM. Epigenetics of cancer stem cells: pathways and therapeutics. Biochim Biophys Acta. 2014;1840:3494–3502.
13. Suzuki H, Yamamoto E, Maruyama R, Niinuma T, Kai M. Biological significance of the CpG island methylator phenotype. Biochim Biophys Res Commun. 2014;455:35–42.
14. Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci. 2013;14:16365–16385.
15. Jones P. The cancer epigenome. Genome. 2013;56:540–541.
16. Bodega B, Orlando V. Repetitive elements dynamics in cell identity programming, maintenance and disease. Curr Opin Cell Biol. 2014;31C: 67–73.
17. Hancks DC, Kazazian HH Jr. Active human retrotransposons: variation and disease. Curr Opin Genet Dev. 2012;22:191–203.
18. Sciamanna I, Gualtieri A, Piazza PV, Spadafora C. Regulatory roles of LINE-1-encoded reverse transcriptase in cancer onset and progression. Oncotarget. 2014;5:8039–8051.
19. Kitkumthorn N, Mutirangura A. Long interspersed nuclear element-1 hypomethylation in cancer: biology and clinical applications. Clin Epigenet. 2011;2:315–330.
20. Turbio JM, Li Y, Ju YS, et al. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science. 2014;345:1251343.
21. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet. 2012;13:679–692.
22. West A, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124:30–39.
23. Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein Cell. 2014;5:265–296.
24. Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013;26:465–484.
25. Barrow TM, Michels KB. Epigenetic epidemiology of cancer. Biochem Biophys Res Commun. 2014;455:70–83.
26. Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metabolism. 2015;64(3 Suppl 1):S16–S21.
27. Nalejska E, Maczynska E, Lewandowska MA. Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther. 2014;18:273–284.
28. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012;12:621–628.
29. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793–795.
30. Lee HZ, Kwitkowski VE, Del Valle PL, et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin Cancer Res. March 23, 2015. [Epub ahead of print.]
31. Dhanak D, Jackson P. Development and classes of epigenetic drugs for cancer. Biochem Biophys Res Commun. 2014;455:58–69.
32. Lakshmaiah KC, Jacob LA, Aparna S, Lokanatha D, Saldanha SC. Epigenetic therapy of cancer with histone deacetylase inhibitors. J Cancer Res Ther. 2014;10:469–478.
33. De Souza C, Chatterji BP. HDAC inhibitors as novel anti-cancer therapeutics. Recent Pat Anticancer Drug Discov. March 17, 2015. [Epub ahead of print.]
34. Campbell RM, Tummino P. Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest. 2014;124:64–70.
35. Andreoli F, Barbosa AJ, Parenti MD, Del Rio A. Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des. 2013;19:578–613.
36. Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54:716–727.
37. Verma SK. Recent progress in the discovery of epigenetic inhibitors for the treatment of cancer. Methods Mol Biol. 2015;1238: 677–688.
38. Azad N, Zahnow CA, Rudin C, Baylin SB. The future of epigenetic therapy in solid tumours – lessons from the past. Nat Rev Clin Oncol. 2013;10:256–266.
39. Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14:623–631.
40. Ben Lassoued A, Nivaggioni V, Gabert J. Minimal residual disease testing in hematologic malignancies and solid cancer. Expert Rev Mol Diagn. 2014;14:699–712.
41. Treppendahl MB, Kristen LS, Gronbaek. Predicting response to epigenetic therapy. J Clin Invest. 2014;124:47–55.
42. Kanai Y, Arai E. Multilayer-omics analyses of human cancers: exploration of biomarkers and drug targets based on the activities of the International Human Epigenome Consortium. Front Genet. 2014;5:24.
43. Wee S, Dhanak D, Li H, et al. Targeting epigenetic regulators for cancer therapy. Ann N Y Acad Sci. 2014;1309:30–36.
44. Ahuja N, Easwaran H, Baylin SB. Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest. 2014;124:56–63.
45. Falahi F, van Kruchten M, Martinet N, Hospers G, Rots MG. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer. Breast Cancer Res. 2014;16:412.
46. Neureiter D, Jager T, Ocker M, Kiesslich T. Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol. 2014;20:7830–7848.
47. Nie J, Liu L, Li Xiang, Han W. Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors. Cancer Lett. 2014;354:12–20.
48. Li H, Chiappinelli KB, Guzzetta AA, et al. Immune regulation by low doses of DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014;5:587–598.
49. Sigalotti L, Fratta E, Coral S, Maio M. Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol Ther. 2014;142:339–350.
50. Bedi U, Mishra VK, Wasilewski D, Schell C, Johnsen S. Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer. Oncotarget. 2014;5:2016–2029.
51. Tian Y, Arai E, Gotoh M, Komiyama M, Fujimoto H, Kanai Y. Prognostication of patients with clear cell renal cell carcinomas based on quantification of DNA methylation levels of CpG island methylator phenotype marker genes. BMC Cancer. 2014;14:772.
52. Doudna J, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346:1258096.
53. Singh VK, Kalsan M, Kumar N, Saini A, Chandra R. Induced pluripotent stem cells applications in regenerative medicine, disease modeling, and drug discovery. Front Cell Dev Biol. 2015;3:2.